| Literature DB >> 28005216 |
Helen Galloway1, Emily Newman2.
Abstract
There are contemporary indicators that parent proxy-ratings and child self-ratings of a child's quality of life (QoL) are not interchangeable. This review examines dual informant studies to assess parent-child agreement on the QoL of children with attention-deficit/hyperactivity disorder. A systematic search of four major databases (PsycINFO, MEDLINE, EMBASE and Cochrane databases) was completed, and related peer-reviewed journals were hand-searched. Studies which reported quantitative QoL ratings for matched parent and child dyads were screened in accordance with relevant inclusion and exclusion criteria. Key findings were extracted from thirteen relevant studies, which were rated for conformity to the recommendations of an adapted version of the STROBE statement guidelines for observational studies. In the majority of studies reviewed, children rated their QoL more highly than their parents. There was some evidence for greater agreement on the physical health domain than psychosocial domains.Entities:
Keywords: ADHD; Attention-deficit/hyperactivity disorder; Children; Parent; Parent–child agreement; Quality of life
Mesh:
Year: 2016 PMID: 28005216 PMCID: PMC5323486 DOI: 10.1007/s12402-016-0210-9
Source DB: PubMed Journal: Atten Defic Hyperact Disord ISSN: 1866-6116
Fig. 1Flow chart detailing the study selection and exclusion process
Adaptations to the STROBE checklist criteria
| Criterion 1 | Title/abstract—reduced to one criterion |
|---|---|
| Criterion 4 | Setting—broken down to further criteria of (a) ‘location’ and (b) ‘relevant dates’ |
| Criterion 8 | Measurement—altered to indicate use of valid/reliable outcome measures appropriate to the population and for use with parent/child dyads |
| Criterion 9 | Bias—altered to indicate active control for bias rather than the authors’ description |
| Criterion 12 | Statistical methods: parts (b), (d) and (e) removed |
| Criterion 13 | Participants—part (c) ‘consider use of a flow diagram’ removed |
| Criterion 16 | Main results—reduced to one criterion |
| Criterion 19 | Limitations—broken down to further criteria of (a) ‘sources of potential bias or imprecision’ and (b) ‘direction and magnitude of potential bias’ |
Characteristics of included studies
| Author (year), country | QoL Measure | Sample characteristics (all ADHD samples include matched QoL dyads) | Design | Main findings relevant to current review ( | Database | Co-morbidities | Domains |
|---|---|---|---|---|---|---|---|
| Thaulow and Jozefiak ( | ILC | Age range 8–15.5 | Case–control (comparison of QoL in children with ADHD and children with anxiety/depression) | In the ADHD group, children’s self-reported QoL was significantly higher than the parent-reported QoL ( | N/A | Not excluded | No only totals for QoL measure. |
| Sciberras et al. ( | Peds-QL | Age range 8–18 | Cross-sectional (children’s experiences of ADHD) | Children rated their QoL higher than their parents rated them for total QoL scores and on all domains except physical functioning. Total: mean diff. = −11.6, 95% CI’s −18.64 to −4.70, | PsycINFO | Not excluded | Yes |
| Marques et al. ( | Peds-QL | Age range 8–12 | Cross-sectional (with comparison group) (parent–child comparison of QoL) | Both children and parents rated QoL as lower in ADHD group than control group on all domains. Good concordance between parents and children on all domains except school functioning, which children self-reported higher than parents (mean difference: 14.55, CI 95%: 7.77, 21.33, SD: 3.36). | MEDLINE | Specified no co-morbidities in ADHD group except ODD | Yes |
| Limbers et al. ( | Peds-QL | Age range 5–18 | Cross-sectional | Children rated QoL higher than parents for total QoL score (mean diff. = 8.57, | EMBASE | Not excluded | Yes |
| Limbers et al. ( | Peds-QL | Age range 5–18 | Case–control | Group 1: no statistically significant differences between parent- and child-rated mean QoL scoresa, but sample size was small ( | PsycINFO | Not excluded | Yes |
| Flapper and Schoemaker ( | DUX-25 and TACQOL | Age range 7–10 years 8 months | Double-blind placebo-controlled clinical trial (effects of methylphenidate on QoL) | DUX-25: no significant differences between parent and child reports for total scores but over some domains (physical | PsycINFO | Excluded except for developmental coordination disorder (DCD) | Yes |
| Varni and Burwinkle ( | Peds-QL | Age range 5–16 | Case–control (population based Peds-QL validation study) | Good reliability for total scale score (Cronbach’s | MEDLINE | Excluded | Yes |
| Klassen et al. ( | CHQ | Age range 10–17 | Cross-sectional | Children self-reported significantly higher QoL than parents on 4 domains: behaviour (mean diff. = 22.9, 95% CI’s 17.6–28.3, SD 19.8, | PsycINFO | Excluded | Yes |
| Schei et al. ( | ILC | Age range 13–18 | Case–control (impact of emotional and conduct problems on QoL in ADHD) | For the ADHD only group, adolescents reported higher total QoL scores than parents ( | N/A | Excluded for direct comparison with ADHD + co-morbid conditions | No only totals |
| Jafari et al. ( | Peds-QL | Age range 8–17 | Cross-sectional (parent and child comparison on QoL) | Children rated their total QoL as higher than parents (mean diff. = 5.33, 95% CI’s −10.6 to −0.06, | PsycINFO | Information not provided | Yes |
| Pongwilairat et al. ( | Peds-QL | 46 ADHD 94 healthy control children (information not provided) | Cross-sectional (QoL of children with ADHD) | Means show children rate their total QoL higher than parents (mean diff. = 146, 95% CI’s 20.1–272.2, | EMBASE | Information not provided | Yes |
| Bastiaansen et al. ( | Peds-QL | Age range 6–18 | Cross-sectional (QoL in children with psychiatric disorders) | For ADHD group, children self-reported higher mean QoL scores than parents across all domains | PsycINFO | Excluded for direct comparisons with other conditions | Yes |
| Gürkan et al. ( | Peds-QL | Age range 8–14 | Open-label trial (psychiatric symptoms and methylphenidate) | Children rated their QoL better than their parents for total QoL score at baseline (mean diff. = 5.4, 95% CI’s 0.2–10.6, | EMBASE | Excluded | Yes |
QoL quality of life, Peds-QL Paediatric Quality of Life Inventory 4.0 generic core scales (Varni et al. 1999), ILC inventory of life quality in children and adolescents (Mattejat and Remschmidt 2006), CHQ Child Health Questionnaire (Landgraf et al. 1996), DUX-25 Dutch-Child-AZL-TNO-Quality-of-Life (Kolsteren et al. 2001), TACQOL TNO-AZL-Child-Quality-of-Life (Vogels et al. 1998)
aStatistical analysis of mean differences between groups was carried out by the author of the review based on data reported in the article
Quality ratings of included studies
| Items (Y/N) | Thaulow and Jozefiak ( | Sciberras et al. ( | Marques et al. ( | Limbers et al. ( | Limbers et al. ( | Flapper and Schoemaker ( | Varni and Burwinkle ( | Klassen et al. ( | Schei et al. ( | Jafari et al. ( | Pongwilairat et al. ( | Bastiaansen et al. ( | Gürkan et al. ( |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1. Title and abstract | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y |
| 2. Rationale | N | Y | Y | Y | Y | Y | Y | Y | Y | Y | N | Y | Y |
| 3. Objectives | N | Y | Y | Y | Y | Y | Y | Y | N | Y | N | Y | Y |
| 4. Study design | Y | Y | Y | Y | Y | Y | Y | N | Y | Y | N | Y | Y |
| 3. (a) Location | Y | Y | Y | Y | Y | Y | Y | Y | Y | N | Y | Y | Y |
| (b) Relevant dates | Y | Y | N | Y | N | N | Y | Y | Y | N | N | Y | N |
| 6. (a) Participants | N | Y | Y | Y | Y | Y | Y | Y | Y | N | N | Y | Y |
| (b) Control group | Y | N/A | N | Y | N | N | Y | N/A | Y | Y | N | N/A | N/A |
| 7. Variables | Y | N | Y | Y | Y | Y | Y | Y | Y | N | Y | Y | Y |
| 8. Measurement | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y |
| 9. Bias | Y | Y | N | Y | Y | Y | Y | N | Y | N | N | N | Y |
| 10. Study size (rationale) | N | N | N | N | N | Y | N | N | N | N | N | N | N |
| 11. Quantitative variables | Y | Y | Y | Y | Y | Y | Y | Y | Y | N | Y | Y | Y |
| 12. (a) Statistical methods | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y |
| (c) Missing data | Y | N | N | N | N | N | Y | N | Y | N | Y | N | N |
| 13. (a) Participants | Y | Y | Y | N | Y | Y | Y | Y | Y | N | Y | Y | Y |
| (b) Non-participation | Y | N | N | N | N | Y | N | Y | Y | N | N | N | Y |
| 14. (a) Sample characteristics | Y | Y | N | Y | Y | Y | Y | Y | Y | N | Y | Y | Y |
| (b) Missing data | N | N | N | Y | N | N | Y | N | Y | N | Y | Y | N |
| 15. Outcome data | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y |
| 16. Main results | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y |
| 17. Other analyses | Y | Y | Y | Y | N/A | Y | Y | Y | N/A | N/A | N/A | Y | Y |
| 18. Key results | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y |
| 19. Limitations (a) sources | N | Y | Y | Y | Y | N | Y | Y | Y | N | Y | Y | N |
| (b) Magnitude | N | N | N | N | N | N | Y | Y | N | N | N | N | N |
| 20. Interpretation | Y | Y | N | Y | Y | Y | Y | Y | Y | Y | N | Y | Y |
| 21. Generalisability | Y | Y | N | Y | Y | N | Y | Y | Y | Y | N | Y | N |
| 22. Funding | Y | Y | Y | Y | Y | N | Y | N | Y | N | N | Y | Y |
| Item no. | Recommendation | |
|---|---|---|
| Title and abstract | 1 | (a) Indicate the study’s design with a commonly used term in the title or the abstract |
| Introduction | ||
| Background/rationale | 2 | Explain the scientific background and rationale for the investigation being reported |
| Objectives | 3 | State-specific objectives, including any prespecified hypotheses |
| Methods | ||
| Study design | 4 | Present key elements of study design early in the paper |
| Setting | 5 | Describe the setting, locations and relevant dates, including periods of recruitment, exposure, follow-up and data collection |
| Participants | 6 | (a) |
| Variables | 7 | Clearly define all outcomes, exposures, predictors, potential confounders and effect modifiers. Give diagnostic criteria, if applicable |
| Data sources/measurement | 8a | For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group |
| Bias | 9 | Describe any efforts to address potential sources of bias |
| Study size | 10 | Explain how the study size was arrived at |
| Quantitative variables | 11 | Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why |
| Statistical methods | 12 | ( |
| Results | ||
| Participants | 13a | (a) Report numbers of individuals at each stage of study—e.g. numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed |
| Descriptive data | 14a | (a) Give characteristics of study participants (e.g. demographic, clinical, social) and information on exposures and potential confounders |
| Outcome data | 15a |
|
| Main results | 16 | (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (e.g. 95% confidence interval). Make clear which confounders were adjusted for and why they were included |
| Other analyses | 17 | Report other analyses done—e.g. analyses of subgroups and interactions, and sensitivity analyses |
| Discussion | ||
| Key results | 18 | Summarise key results with reference to study objectives |
| Limitations | 19 | Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias |
| Interpretation | 20 | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies and other relevant evidence |
| Generalisability | 21 | Discuss the generalisability (external validity) of the study results |
| Other information | ||
| Funding | 22 | Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based |
An explanation and elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the websites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/ and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org
aGive information separately for cases and controls in case–control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies